Powered by 
Technavio
MetrioPharm AG | Data-Driven Analysis and Industry Review
Published: August 28, 2024MetrioPharm AG is a Swiss-based biotech company specializing in the research, development, and commercialization of cannabinoid-based therapies. Founded in 2016, the company focuses on addressing unmet medical needs by leveraging the therapeutic potential of cannabinoids, the active compounds in cannabis. MetrioPharm's proprietary technology enables the production of pharmaceutical-grade cannabinoids using a continuous manufacturing process, ensuring consistent quality and safety. Their lead product, MP1032, is a cannabidiol (CBD) formulation in late-stage clinical development for the treatment of chronic pain and inflammatory diseases. MetrioPharm's mission is to bring effective and safe cannabinoid-based therapies to patients, improving their quality of life.'
1. MetrioPharm AG is a clinical-stage biotechnology company specializing in the development of metformin-based therapies for the treatment of various diseases, including cancer and neurodegenerative disorders.
2. The company's lead product, MP1032, is a novel, long-acting formulation of metformin that has shown potential in preclinical studies to enhance the efficacy of chemotherapy and improve treatment outcomes in cancer patients.
3. MetrioPharm AG has a strong intellectual property portfolio, with multiple patents granted and pending for its proprietary technologies, including its modified-release metformin formulations and targeted delivery systems.
4. The company has a robust pipeline, with several clinical trials ongoing or planned for MP1032 in various indications, including pancreatic cancer, colorectal cancer, and non-alcoholic steatohepatitis (NASH).
5. MetrioPharm AG has strategic collaborations and partnerships with leading academic institutions and pharmaceutical companies, including the University of Tuebingen, the German Cancer Research Center (DKFZ), and Merck KGaA, to advance its research and development efforts.
1. MetrioPharm AG is a leading provider of Business Intelligence (BI) solutions in the life sciences industry, specializing in data analytics for pharmaceutical and biotech companies.
2. Their BI platform integrates and analyzes data from various sources, including clinical trials, regulatory affairs, and commercial operations, to provide actionable insights for decision-making.
3. MetrioPharm AG's BI solutions enable customers to optimize their drug development processes, improve regulatory compliance, and enhance overall business performance.
4. They offer customizable reporting and visualization tools, allowing clients to gain a deeper understanding of their data and identify trends and patterns that can inform strategic planning.
5. MetrioPharm AG's team of experts provides consulting services and training to help clients maximize the value of their BI investments and ensure successful implementation and adoption of their solutions.
Browse Our Research Portfolio In MetrioPharm AG Markets
Health Care
Biotechnology and Life Sciences
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
